Reardon Tighe 4
4 · Synthorx, Inc. · Filed Jan 24, 2020
Insider Transaction Report
Form 4
Synthorx, Inc.THOR
Reardon Tighe
Acting Chief Financial Officer
Transactions
- Disposition from Tender
Common Stock
2020-01-23$68.00/sh−1,682,086$114,381,848→ 0 total(indirect: By Avalon X SPV I, L.P.) - Disposition to Issuer
Employee Stock Option (right to buy)
2020-01-23$57.00/sh−30,000$1,710,000→ 0 totalExercise: $11.00Exp: 2028-12-05→ Common Stock (30,000 underlying) - Disposition from Tender
Common Stock
2020-01-23$68.00/sh−43,688$2,970,784→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2020-01-23$63.36/sh−18,723$1,186,289→ 0 totalExercise: $4.64Exp: 2028-08-29→ Common Stock (18,723 underlying)
Footnotes (3)
- [F1]The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any.
- [F2]This option, which was immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,186,289.28, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
- [F3]This option, which provided for vesting of 100% of the shares subject to the option upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,710,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).